ClinicalTrials.gg
RecruitingNCT06450444RECLAIMUpdated Aug 6, 2026

The RECLAIM Study.

An interventional study of PRIMUS in Chronic Migraine and High Frequency Episodic Migraine, sponsored by Salvia BioElectronics. Recruiting at 11 sites in 3 countries. Open to participants aged 18 Years to 84 Years. Per ClinicalTrials.gov, last updated 2026-08-06.

Sponsored by Salvia BioElectronics · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 4 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years to 84 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety and performance, including clinical benefit, of the PRIMUS System for the treatment of Resistant Migraine.

02

Conditions studied

  • Chronic Migraine
  • High Frequency Episodic Migraine

Browse trials for

03

In context

Migraine Disorders

1,657 studies on the registry are indexed under Migraine Disorders; 339 are open to participants now.

This study's planned enrollment of 110 is above the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.

Browse Migraine Disorders studies →

Lead sponsor

Salvia BioElectronics is the lead sponsor of 5 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 84 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of migraine as defined by the ICHD-3 Classification (with or without aura) with a history of chronic or high-frequency episodic migraine for at least 1 year prior to screening
  • Failure of 3 or more preventive pharmacological therapies
  • Stable on preventive migraine treatments
  • Psychologically stable

Exclusion criteria

Exclusion Criteria:

  • Concomitant invasive or non-invasive neuromodulation
  • Previous exposure to an implantable neuromodulation device for headache
  • Have an existing active implantable medical device nearby the implant location (e.g. DBS, cochlear implant)
  • Use of onabotulinum toxin A injections for the treatment of migraine in the past 3 months.
  • Use of local injections in the occipital or supra-orbital region in the past 3 months prior to enrollment.
  • Not pregnant, nursing or not using
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    Cohort 1 - Treatment Group

    Active therapy modality

    Device: PRIMUS

  • Other
    Cohort 1 - Control Group

    Sham therapy

    Device: PRIMUS

  • Experimental
    Cohort 2 - Therapy V

    Active therapy modality

    Device: PRIMUS

  • Experimental
    Cohort 2 - Therapy D

    Active therapy modality

    Device: PRIMUS

Interventions

  • DevicePRIMUS

    The Salvia PRIMUS System is designed to provide subcutaneous neurostimulation to the branches of the trigeminal and occipital nerves.

06

What researchers measure

Primary outcomes

  1. Safety Evaluation

    The incidence of serious procedure, device and/or stimulation-related adverse events.

    Time frame: 12 weeks

  2. Effectiveness Evaluation

    Proportion of subjects with ≥ 30% reduction in the number of Monthly Migraine Days (MMD), in randomized arms.

    Time frame: 12 weeks

07

Study locations

8 of 11 sites recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06450444
Lead sponsor
Salvia BioElectronics
Responsible party
Sponsor
First posted
Jun 10, 2024
Start date
Jun 24, 2024
Primary completion
Apr 1, 2027 (estimated)
Completion
Jan 31, 2029 (estimated)
Last update
Aug 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion